Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival
R. A. MouraInstituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, PortugalRita CascãoRheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, 2Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, 3Rheumatology Department, Centro Hospitalar de Lisboa Ocidental, EPE, Hospital Egas Moniz, 4Microvascular Biology and Inflammation Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, 5Center for Neurosciences and Cell Biology, Autoimmunity Group, Coimbra, 6Cellular Immunology Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon and 7Instituto Gulbenkian de Ciência, Oeiras, PortugalInês P. PerpétuoRheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, 2Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, 3Rheumatology Department, Centro Hospitalar de Lisboa Ocidental, EPE, Hospital Egas Moniz, 4Microvascular Biology and Inflammation Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, 5Center for Neurosciences and Cell Biology, Autoimmunity Group, Coimbra, 6Cellular Immunology Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon and 7Instituto Gulbenkian de Ciência, Oeiras, PortugalHelena CanhãoRheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, 2Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, 3Rheumatology Department, Centro Hospitalar de Lisboa Ocidental, EPE, Hospital Egas Moniz, 4Microvascular Biology and Inflammation Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, 5Center for Neurosciences and Cell Biology, Autoimmunity Group, Coimbra, 6Cellular Immunology Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon and 7Instituto Gulbenkian de Ciência, Oeiras, PortugalElsa Vieira‐SousaRheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, 2Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, 3Rheumatology Department, Centro Hospitalar de Lisboa Ocidental, EPE, Hospital Egas Moniz, 4Microvascular Biology and Inflammation Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, 5Center for Neurosciences and Cell Biology, Autoimmunity Group, Coimbra, 6Cellular Immunology Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon and 7Instituto Gulbenkian de Ciência, Oeiras, PortugalAF MourãoRheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, 2Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, 3Rheumatology Department, Centro Hospitalar de Lisboa Ocidental, EPE, Hospital Egas Moniz, 4Microvascular Biology and Inflammation Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, 5Center for Neurosciences and Cell Biology, Autoimmunity Group, Coimbra, 6Cellular Immunology Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon and 7Instituto Gulbenkian de Ciência, Oeiras, PortugalAna Maria RodriguesRheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, 2Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, 3Rheumatology Department, Centro Hospitalar de Lisboa Ocidental, EPE, Hospital Egas Moniz, 4Microvascular Biology and Inflammation Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, 5Center for Neurosciences and Cell Biology, Autoimmunity Group, Coimbra, 6Cellular Immunology Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon and 7Instituto Gulbenkian de Ciência, Oeiras, PortugalJoaquim Polido‐PereiraRheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, 2Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, 3Rheumatology Department, Centro Hospitalar de Lisboa Ocidental, EPE, Hospital Egas Moniz, 4Microvascular Biology and Inflammation Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, 5Center for Neurosciences and Cell Biology, Autoimmunity Group, Coimbra, 6Cellular Immunology Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon and 7Instituto Gulbenkian de Ciência, Oeiras, PortugalM Viana QueirózRheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, 2Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, 3Rheumatology Department, Centro Hospitalar de Lisboa Ocidental, EPE, Hospital Egas Moniz, 4Microvascular Biology and Inflammation Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, 5Center for Neurosciences and Cell Biology, Autoimmunity Group, Coimbra, 6Cellular Immunology Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon and 7Instituto Gulbenkian de Ciência, Oeiras, PortugalH.S. RosárioRheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, 2Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, 3Rheumatology Department, Centro Hospitalar de Lisboa Ocidental, EPE, Hospital Egas Moniz, 4Microvascular Biology and Inflammation Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, 5Center for Neurosciences and Cell Biology, Autoimmunity Group, Coimbra, 6Cellular Immunology Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon and 7Instituto Gulbenkian de Ciência, Oeiras, PortugalMargarida Souto‐CarneiroRheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, 2Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, 3Rheumatology Department, Centro Hospitalar de Lisboa Ocidental, EPE, Hospital Egas Moniz, 4Microvascular Biology and Inflammation Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, 5Center for Neurosciences and Cell Biology, Autoimmunity Group, Coimbra, 6Cellular Immunology Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon and 7Instituto Gulbenkian de Ciência, Oeiras, PortugalLuís GraçaRheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, 2Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, 3Rheumatology Department, Centro Hospitalar de Lisboa Ocidental, EPE, Hospital Egas Moniz, 4Microvascular Biology and Inflammation Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, 5Center for Neurosciences and Cell Biology, Autoimmunity Group, Coimbra, 6Cellular Immunology Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon and 7Instituto Gulbenkian de Ciência, Oeiras, PortugalJoão Eurico FonsecaRheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, 2Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, 3Rheumatology Department, Centro Hospitalar de Lisboa Ocidental, EPE, Hospital Egas Moniz, 4Microvascular Biology and Inflammation Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, 5Center for Neurosciences and Cell Biology, Autoimmunity Group, Coimbra, 6Cellular Immunology Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon and 7Instituto Gulbenkian de Ciência, Oeiras, Portugal
2010en
ABI
Аннотация
OBJECTIVES: B cells play an important role in the perpetuation of RA, particularly as autoantibody-producing cells. The ICs that further develop deposit in the joints and aggravate the inflammatory process. However, B-cell contribution in the very early stage of the disease remains unknown. The main goal of this work was to determine the concentration of cytokines potentially relevant for B-cell activation in serum from very early polyarthritis patients, with <6 weeks of disease duration, who latter on evolved into very early RA (VERA). METHODS: A proliferation-inducing ligand (APRIL), B-cell activating factor (BAFF) and IL-21 levels were measured by ELISA in the serum of VERA, other very early arthritis (VEA), established RA patients and controls. SF samples of established RA were also analysed. RESULTS: VERA patients have higher levels of APRIL and BAFF as compared with VEA, established RA and controls. Furthermore, APRIL and BAFF levels are also significantly elevated in RA-SF when compared with serum. CONCLUSIONS: The increased levels of APRIL and BAFF in VERA patients suggests that B-cell activation and the development of autoreactive B-cell responses might be crucial in early phases of RA. Therefore, APRIL and BAFF could be promising targets for therapy in the early phase of RA.
Перевод пока недоступен
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0